EGFR and cancer: In our long-term in vivo efficacy study, we demonstrated that licofelone and gefitinib can target COX-2, 5-LOX, EGFR, and cancer stem cell marker DclK1, and can potently inhibit PanIN progression to PDAC without any side effects.